share_log

Jefferies Maintains Buy on ProKidney, Lowers Price Target to $6

Benzinga ·  Jun 11 02:17

Jefferies analyst Kelly Shi maintains ProKidney (NASDAQ:PROK) with a Buy and lowers the price target from $15 to $6.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment